The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|September 2, 2007
- Pharmaceutical Technology-09-02-2007
- Volume 31
- Issue 9
Useful Contacts
Useful Contacts
Advertisement
Useful Contacts
Indian Drug Manufacturers' Association (IDMA)
Mumbai
tel. +91 22 2494 4624
Indian Pharmaceutical Association (IPA)
Mumbai
tel: +91 22 2667 0742
Indian Pharma Machinery Manufacturers' Association (IPMMA)
Mumbai
tel: +91 22 2578 6007
Organization of Pharmaceutical Producers of India (OPPI)
Mumbai,
Pharmaceuticals Export Promotion Council (Pharmexcil)
Hyderabad
tel: +91 40 2373 5462
For further information about the above companies, please email
Articles in this issue
about 19 years ago
Advances in Asymmetric Synthesisabout 19 years ago
A Call for FDA Inspectionsabout 19 years ago
CMOs Join Pharma Facility Swap Meetabout 19 years ago
Supplements to the PQRI Workshop Resultsabout 19 years ago
How to Gain Approval Overseasabout 19 years ago
Pharma Capsulesabout 19 years ago
Printing Digital Labelsabout 19 years ago
Enhancing Drug Safetyabout 19 years ago
The Challenges and Opportunities in ICH Q10Advertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
5